NEXGEL Inc (NASDAQ:NXGL) has announced the appointment of Scott Henry as a new independent director to the company's board effective immediately, he will also serve as a member of the board's Audit Committee.
Henry is a managing director and senior research analyst at ROTH Capital Partners with 20 years of sell-side coverage in the pharmaceutical, biotechnology and medical device sectors. He has previously held positions with firms including Oppenheimer, Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co.
"Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, chief executive officer of NEXGEL in a statement. "Additionally, his vast network within the investment community and his extensive knowledge of the small and microcap company landscape will be invaluable towards supporting our growth initiatives going forward. We are grateful to have Scott as part of our team."
READ: NEXGEL launches new hydrogel dressing to treat turf burns and protect athletic wounds
NEXGEL noted that Henry has received numerous awards, including rankings in the Wall Street Journal 'Best on the Street' stock picking survey, Forbes/Zacks Investment Research 'Best Analysts' for the drugs category and Forbes.com/StarMine rankings for earnings estimate accuracy. His investment views have been cited in the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS MarketWatch and Bloomberg. He attended the University of Rhode Island and received an MBA with distinction from Cornell University.
Henry commented: "After spending extensive time with Adam and the rest of the senior leadership team, I was excited to join the NEXGEL team as a member of the Board and Audit Committee. NEXGEL presents a unique situation with solid assets, talented people and significant growth potential. Leveraging my experience and industry relationships, I believe that together, we can capitalize on these opportunities."
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pennsylvania, the company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Contact the author at jon.hopkins@proactiveinvestors.com